SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
3.6k Views
SK Shieldus IPO - Peer Comparison - Better Top Line Growth, Worse Margin Decline
SK Shieldus (SKS) aims to raise around US$800m via issuing a mix of primary and secondary shares in its Korea IPO. In this note, we undertake a...
596 Views
No more insights